Remicade (infliximab) denied for missing prior authorization by UnitedHealthcare?

This UnitedHealthcare commercial policy (effective 02.01.2026) addresses the use of infliximab products including Avsola, Inflectra, Remicade, and Renflexis , and applies to billing codes J1745, Q5103, Q5104, and Q5121 . UHC designates Avsola and Inflectra as the preferred infliximab products for UHC commercial plans , and members already on Remicade, Renflexis, or other non-preferred infliximab product will be required to change therapy to Inflectra or Avsola unless they meet the exception criteria . To obtain Remicade specifically, the policy requires documentation of a trial of at least 14 weeks of Inflectra or Avsola resulting in minimal clinical response, OR a physician attestation that in their clinical opinion the clinical response would be expected to be superior with Remicade than with Inflectra and Avsola , or alternatively documentation of intolerance, contraindication, or adverse event to the preferred biosimilars with a physician attestation that the same event would not be expected to occur with Remicade . Indication-specific criteria require disease-appropriate step therapy — for example, ankylosing spondylitis requires history of failure to two NSAIDs at maximally indicated doses, each used for at least 4 weeks, unless contraindicated, or prior treatment with a systemic targeted immunomodulator FDA-approved for ankylosing spondylitis ; plaque psoriasis requires greater than or equal to 3% body surface area involvement, or palmoplantar, facial, or genital involvement plus failure of a topical therapy. Patients must not be receiving infliximab in combination with another systemic targeted immunomodulator (e.g., adalimumab, Cimzia, Enbrel, Orencia, Simponi, Rinvoq, Xeljanz) for treatment of the same indication , and dosing must be according to FDA-labeled dosing for the indication . Prior authorization is required, and the policy notes the patient must not have FDA-labeled contraindications and must be tested for latent TB per prescribing information, with treatment begun if positive .

- For forced biosimilar switching: cite the ACR position that coverage for non-preferred products should consider patient-specific exception criteria, and ACR has urged UHC to allow existing patients to continue on their current medication and proposed additional exception criteria for patient protection ; also reference AGA's negotiated exceptions that adult patients currently on induction of Remicade for less than 18 months will not be required to switch, and adult patients having a flare of active disease, and hence are not stable, will not be required to switch - For pediatric IBD denials of Remicade continuation: cite United's agreement to modify its coverage policy to allow pediatric patients 16 years of age and younger currently on Remicade to remain on Remicade if that is the recommendation of the treating physician , supported by NASPGHAN/AGA/ACG/ASGE consensus - For step therapy in Crohn's disease: cite the ACG Clinical Guideline for Crohn's Disease in Adults and AGA Care Pathway recommending early anti-TNF therapy for moderate-to-severe disease and high-risk features (fistulizing, stricturing, perianal, young age at diagnosis) — aligns with UHC's own high-risk criteria language - For step therapy in rheumatoid arthritis: cite the 2021 ACR Guideline for RA Treatment supporting biologic DMARDs (including TNFi) after inadequate response to methotrexate; for ankylosing spondylitis cite the 2019 ACR/SAA/SPARTAN AS Guideline strongly recommending TNFi after NSAID failure - For plaque psoriasis criteria: cite the AAD-NPF 2019 Guidelines of Care for the Management of Psoriasis with Biologics supporting infliximab for moderate-to-severe disease and special-site involvement (palmoplantar, facial, genital), matching UHC's BSA/special-site criteria - For non-medical switching/efficacy concerns: cite the NOR-SWITCH randomized controlled trial (Jørgensen et al., Lancet 2017) demonstrating non-inferiority of CT-P13 biosimilar to originator infliximab — but conversely, a documented loss of response or infusion reaction on a biosimilar meets UHC's own exception pathway for Remicade - For concomitant biologic denial: clarify in the appeal that the patient is transitioning therapies (not on simultaneous biologics) with appropriate washout, addressing UHC's combination-therapy exclusion language

## Why UnitedHealthcare Requires Prior Authorization for Remicade (Infliximab)

UnitedHealthcare requires prior authorization (PA) for Remicade (infliximab) across most plan types. Infliximab is a high-cost biologic administered by intravenous infusion, and UHC's standard utilization-management program requires advance clinical review before claims will be paid. A claim submitted without a valid, active PA on file — or with a PA that was approved for a different indication, site of care, or time period — will result in an automatic denial. This is an administrative process failure, not a clinical judgment that the treatment is inappropriate.

## Why This Denial Is Appealable

PA-required denials have two appeal paths: (1) prospective — submit or resubmit the PA with complete clinical documentation to obtain authorization for upcoming infusions; and (2) retrospective — if infusions have already occurred, appeal for retroactive authorization by demonstrating that the clinical criteria for coverage were met at the time of service, even if the PA was not obtained in advance. Retroactive approval is available and is granted when plans confirm the clinical criteria were satisfied.

## Federal Appeal Framework

• Internal appeal: Under ERISA §503 and ACA §2719, UHC must conduct a full-and-fair internal review of any PA denial. The denial letter must state the specific clinical criteria not met and must provide all information used in the determination.
• External review: After a final internal denial, an independent external review is available within approximately four months. The external reviewer applies objective clinical standards and is not bound by UHC's internal PA criteria.
• Expedited review: UHC is required to offer an expedited PA and appeal process for urgent situations. If the patient's condition would be seriously jeopardized by delay, request expedited processing immediately.

## Documentation to Gather

1. UHC's current PA criteria for infliximab — download from UHC's provider portal or request from UHC's clinical team. Identify every required element: qualifying diagnosis, disease severity, required prior therapies, prescriber type, site-of-care requirements, and any ongoing monitoring requirements. 2. Specialist letter of medical necessity — from the treating specialist (gastroenterologist, rheumatologist, or relevant subspecialist). Must address each PA criterion explicitly and map the patient's clinical situation to each requirement. 3. Disease documentation — recent specialist notes with objective disease-activity documentation referenced by date; confirmation of diagnosis with supporting objective findings. 4. Prior-treatment history — dated records for each prior therapy required by the UHC step-therapy protocol (if any), including duration, response, and reason for transition. 5. Infusion site confirmation — UHC may require that infusions occur at a specific site of care (e.g., outpatient hospital, physician office, or UHC-preferred infusion center). Confirm the proposed site meets the plan's requirements.

## Criteria-Mapping Structure

| UHC PA Criterion (copy verbatim from policy) | Patient Chart Evidence (document + date) | |---|---| | Qualifying diagnosis | Specialist note, ICD code, objective confirmation | | Disease severity / activity | Chart note with clinical description | | Prior therapy requirements | Dated medication history with outcomes | | Prescriber specialty requirement | Specialty, NPI, letter | | Site-of-care requirement | Infusion site address and credential | | Authorization period / quantity | Requested frequency and duration |

Submit the PA request and the appeal as a single, organized packet. UHC PA reviewers are working from a checklist; a response that mirrors that checklist item-by-item has the highest success rate.